ARTICLE | Company News
Cortria, Pharmena deal
July 21, 2008 7:00 AM UTC
The companies cross-licensed each other’s assets related to Pharmena’s TRIA-662. The metabolite of niacin is in Phase II testing to treat dyslipidemia with data expected in early 2009. Cortria receiv...